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Treatment  /management  options  include:  
Reversible:  medical  treatment  with  anti-­thyroid  medication  or  nutritional  management  with  an  
iodine-­restricted  diet    
Irreversible/curative:  radio-­iodine  treatment,  surgical  thyroidectomy,  less  common  ultrasound-­
guided  heat  or  ethanol  ablation  of  the  thyroid  gland.    
Ideally,  medical  or  dietary  options  should  be  tried  and  tested  before  considering  the  irreversible  
treatment  options.  Final  decision  for  treatment  should  be  made  together  with  the  owner  taking  
into  account  among  others,  the  cat's  age,  tolerance  of  medications,  owner  finances  and  ability  
to  be  compliant  with  medications,  presence  of  concurrent  disease,  availability  and  willingness  
of  owner  to  pursue  I131.    
  
Anti-­Thyroid  drugs  
The   thioureylene  methimazole  and   its   pro-­drug   carbimazole  are   the  drug  of   choice   for   the  
treatment   of   feline   HT.   They   inhibit   thyroperoxidases   in   the   thyroid   follicular   cells   thereby  
leading  to  a  reversible  decrease  in  the  synthesis  of  thyroid  hormones  (T4  and  T3).    
The  recommended  starting  dose  of  methimazole  is  2.5mg  /  cat  PO  twice  daily,  a  sustained-­
release  formulation  of  carbimazole  is  available  in  some  European  countries  and  is  started  at  
10  or  15  mg,  PO,  once  daily.    
Transdermal  medication  
If   owners  are  unable   to  pill   the   cat   or   if  gastro-­intestinal   side  effects  occur,  a   change   to  a  
transdermal  methimazole  formulation  can  be  tried.  Currently  there  are  no  registered  products  
and  the  cream  has  to  be  produced  by  compounding  pharmacies.  Dosage  usually  is  the  same  
as  with  the  oral  product.  It  is  important  to  instruct  the  owners  to  wear  gloves  to  administer  the  
drug  to  avoid  “self-­therapy”.    
  
Treatment  monitoring  
First   reassessment   is   recommended  after   2-­4  weeks   of   therapy,   depending  on   the   clinical  
condition  of   the   cat   and   the  presence  of   concurrent  disease   (e.g.   cardiac   failure)   and  pre-­
treatment   blood   parameters   (e.g.   urea,   creatinine).   If   euthyroidism   is   not   achieved   after   4  
weeks,   dosage   adjustments   are   usually   made   in   1.25–2.5   mg/day   increments.   Owner  
compliance  must  be  assessed  before  increasing  the  dose.  
Serum  T4  concentration  should  be  maintained  within  the  middle  of  the  reference  interval.  For  
long-­term   treatment,   it   is   very   important   to   avoid   iatrogenic   hypothyroidism   (see   below).  
Findings   of   low   serum   T4   with   high   TSH   concentrations   are   diagnostic   for   iatrogenic  
hypothyroidism,  and  therefore  the  daily  dose  of  methimazole  should  be  decreased.    
  
Adverse  effects  of  medical  therapy    
Adverse  reactions  associated  with  anti-­thyroid  drugs  usually  occur  within  the  first  3  months  of  
starting  therapy,  including  nausea,  vomiting,  lethargy,  diarrhea  and  facial  excoriation.    
Life-­threatening   adverse   reactions   include   agranulocytosis,   thrombocytopenia   and  
hepatopathy,   but   only   rarely  occur.   If   treatment   is   stopped,   clinical   signs  are   reversible.   If  
leukopenia,  eosinophilia,  and  lymphocytosis  are  noted,  they  should  be  closely  monitored,  as  
they  usually  resolve  despite  continuing  treatment.    
Disadvantages  of  medical  therapy  are:    
Compliance,   treatment   intolerance,   efforts   and   costs   associated   with   lifelong   treatment   /  
monitoring.   Another   major   disadvantage   of   medical   therapy   is   that   the   disease   tends   to  
advance  despite   the  medication   (no   cytotoxic  effect  of  methimazole/carbimazole).  There   is  
evidence  that  the  prevalence  of  large  thyroid  tumors,  multifocal  disease,  intrathoracic  thyroid  
masses  and  suspected  malignant  disease  increase  with  disease  duration  in  medically  treated  
cats.    
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Limited-­Iodine  /  iodine-­restricted  Diet    
Iodine  is  essential  in  the  production  of  thyroid  hormones  and  limited  nutritional  availability  of  
iodine  leads  to  reduced  thyroid  hormone  concentrations.  Within  4  to  8  weeks  of  strictly  feeding  
the  commercially  available  diet  (Hill`s  prescription  diet  y/d  Feline  thyroid  health),  approximately  
90%  of  HT  cats  become  euthyroid,  after   12  weeks  almost   all   cats  have  T4  concentrations  
within  the  reference  interval.  So  far,  iatrogenic  hypothyroidism  could  not  be  shown  even  after  
prolonged  feeding  of  the  diet.  A  major  disadvantage  however  is  that  all  other  food,  treats  or  
table  scraps  must  be  strictly  avoided,  because  they  will  counteract  the  effects  of  the  diet  and  
re-­increase  the  T4  concentration.  This  can  be  problematic  in  the  long-­term  management  of  the  
disease.  Also,  the  composition  of  y/d  (rather  low  protein  and  high  carbohydrate  content)  may  
not  be  optimal  in  the  long  run  for  cats.  But,  against  earlier  concerns,  the  diet  can  be  used  in  a  
muti-­cat  household,  where  healthy  cats  have  access  to  the  diet  as  in  a  recent  study  it  could  be  
shown   that   feeding   a   limited-­iodine   diet   for   2   years   to   healthy   adult   cats   did   not   lead   to  
iatrogenic  hypothyroidism  or  goiter.  
  
Surgical  thyroidectomy    
Depending  on  the  experience  of  the  surgeon,  thyroidectomy  can  be  a  good  treatment  option  
especially  if  radio-­Iodine  treatment  is  not  available.  The  risk  of  anesthesia  in  untreated  HT  cats  
is  high  and  to  decrease  peri-­  and  postoperative  mortality,  cats  should  be  medically  treated  and  
stabilized  before  the  surgery.    
Surgical  complications  include  post-­op  laryngeal  paralysis/voice  change,  Horner's  syndrome  
and  iatrogenic  hypoparathyroidism  (hypocalcemia)   if  bilateral  surgery   is  performed.  Calcium  
levels   should   be   monitored   3–7   days   postoperatively   and   hypocalcemia   treated   if   clinical  
symptoms  occur  or  if  concentrations  of  ionized  Calcium  are  in  the  very  low  range.  Recovery  of  
the  parathyroid  gland   function   is  possible   (dependent  on   the  surgical   technic)  but  can  take  
days   to  months.   Temporary   or   permanent   hypothyroidism   (bilateral   thyroidectomy)   is   also  
possible  and  has  to  be  monitored  at  regular  intervals.  Recovery  is  possible,  however  if  clinical  
signs  of  hypothyroidism  develop  or  azotemia  worsens,  levothyroxine  supplementation  should  




Table  1:  Comparison  of  options  for  managing  cats  with  hyperthyroidism    
Treatment  option   Advantage   Disadvantage  
        
Anti-­thyroid  drugs   Reversible  
Easily  available  
Initial   costs   low   and   spread  
over  time    
No  hospitalization    
Not  curative  
Daily  administration    
Compliance  difficult  
Side  effects  possible    
  
Limited-­iodine  diet     Reversible  
Easily  available  
Costs  spread  over  time    
No  hospitalization    
Not  curative  
Only  single  food  required    
Compliance  difficult    
Thyroidectomy     Curative     Anesthesia  and  
hospitalization  required    
High  initial  costs    
Risk  of  postoperative  
hypocalcemia  and  other  
surgical  complications    
Not  effective  for  ectopic  
tissue  
Recurrence  possible  
Radio-­iodine     See  lecture  Prof.  Dr.  M  Peterson    
   3  
Post-­treatment  renal  disease/  insufficiency    
Chronic  kidney  disease  (CKD)  may  be  masked  during  the  hyperthyroid  state  and  due  to  the  
decrease  in  the  glomerular  filtration  rate  during  therapy,  overt  CKD  can  develop  (independent  
of  the  treatment  modality).  Prevalence  of  CKD  varies  between  15  and  60%.  Unfortunately,  to  
date,  there  is  no  clinical  test  that  can  reliably  predict  which  cats  have  concurrent  CKD  that  will  
become  overt  after  treatment  of  the  hyperthyroid  state.    
In  a  recent  study  it  has  been  shown  that  as  a  diagnostic  test   for  masked  CKD  in  untreated  
hyperthyroid  cats,  SDMA  has  a  sensitivity  of  33.3%  and  a  specificity  of  97.7%.  This  means  that  
finding   a   high   serum   SDMA   concentration   in   a   hyperthyroid   cat   can   help   to   predict   the  
development  of  azotemia  after  treatment,  however,  due  to  the  low  sensitivity  a  normal  SDMA  
concentration  cannot  excluded  it.    
Care  must  be  taken  to  avoid  iatrogenic  hypothyroidism  as  it  may  contribute  to  the  development  
of  azotemia  in  cats  treated  for  HT  and  these  cats  may  have  a  shorter  survival  time  compared  
to  azotemic  but  euthyroid  cats.    
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